Evidence map›Paper›PMID 35604323›Full record

ReviewJournal of internal medicine2022

Current concepts regarding Graves' orbitopathy.

Luigi Bartalena, Maria Laura Tanda

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06413043 (Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy), which is not on this map. Cited by 108 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 6 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06413043 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy: A Randomized Control Trial

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2024 to 2025Enrolled78ConditionsThyroid Eye Disease, Graves OphthalmopathyArmsSelenium
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 6 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. IntegratedEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Luigi BartalenaDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.ORCID 0000-0001-8447-5449
Maria Laura TandaDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
University of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graves' orbitopathy (GO) is an orbital autoimmune disorder and the main extrathyroidal manifestation of Graves' disease, the most common cause of hyperthyroidism. GO affects about 30% of Graves' patients, although fewer than 10% have severe forms requiring immunosuppressive treatments. Management of GO requires a multidisciplinary approach. Medical therapies for active moderate-to-severe forms of GO (traditionally, high-dose glucocorticoids) often provide unsatisfactory results, and subsequently surgeries are often needed to cure residual manifestations. The aim of this review is to provide an updated overview of current concepts regarding the epidemiology, pathogenesis, assessment, and treatment of GO, and to present emerging targeted therapies and therapeutic perspectives. Original articles, clinical trials, systematic reviews, and meta-analyses from 1980 to 2021 were searched using the following terms: Graves' disease, Graves' orbitopathy, thyroid eye disease, glucocorticoids, orbital radiotherapy, rituximab, cyclosporine, azathioprine, teprotumumab, TSH-receptor antibody, smoking, hyperthyroidism, hypothyroidism, thyroidectomy, radioactive iodine, and antithyroid drugs. Recent studies suggest a secular trend toward a milder phenotype of GO. Standardized assessment at a thyroid eye clinic allows for a better general management plan. Treatment of active moderate-to-severe forms of GO still relies in most cases on high-dose systemic-mainly intravenous-glucocorticoids as monotherapy or in combination with other therapies-such as mycophenolate, cyclosporine, azathioprine, or orbital radiotherapy-but novel biological agents-including teprotumumab, rituximab, and tocilizumab-have achieved encouraging results.

Indexed as

Graves OphthalmopathyHyperthyroidismThyroid NeoplasmsAntithyroid AgentsAzathioprineBiological FactorsCyclosporineGlucocorticoidsHumansImmunosuppressive AgentsIodine RadioisotopesReceptors, ThyrotropinRituximabAntithyroid AgentsAzathioprineBiological FactorsCyclosporineGlucocorticoidsImmunosuppressive AgentsIodine RadioisotopesReceptors, ThyrotropinRituximabglucocorticoidsGraves’ orbitopathyiscalimabrituximabteprotumumabthyrotropin receptortocilizumabTSH receptor

Identifiers

PMID35604323
PMCPMC9796560
OpenAlexW4281396779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.